Rebecca Michael, PhD; Senior Group Leader, Cell and Molecular Biology Group

There is a high attrition rate during the development of biotherapeutics impacting the high cost of development. Early identification of the preferred expression host for manufacturing, along with lead candidate screening and material supply can help to reduce both attrition rates and cost. Due to the trend towards the increased complexity of protein therapeutics,  the use of early stage in vitro expression to assess and identify risks enables the development of process strategies to mitigate risks as early as possible and maximize the outcome of developing biotherapeutics. Early genetic assessment of expression cell lines can support cell line characterization and can help to confirm identify stability concerns at an early stage.